ARS Pharmaceuticals’ CCO Balances Buy‑Sell Trade, Hinting at Upside Despite Volatile Market
Karas Eric’s June 2026 trades show insider confidence in ARS Pharmaceuticals—buying low, selling high, and boosting buzz for its ImmunoTAC platform.
3 minutes to read